| First Author | Perera AP | Year | 2018 |
| Journal | Mamm Genome | Volume | 29 |
| Issue | 11-12 | Pages | 817-830 |
| PubMed ID | 30206651 | Mgi Jnum | J:279535 |
| Mgi Id | MGI:6283741 | Doi | 10.1007/s00335-018-9783-2 |
| Citation | Perera AP, et al. (2018) NLRP3 inflammasome in colitis and colitis-associated colorectal cancer. Mamm Genome 29(11-12):817-830 |
| abstractText | A low level of inflammation is an integral part of the balance between the immune system and the microbiota in the high antigen environment of the gastrointestinal tract and maintains homeostasis. A failure of this balance can lead to chronic intestinal inflammation and increase the chances to develop colorectal cancer significantly. The underlying mechanisms that link inflammation and carcinogenesis are not clear but the molecular platforms of the inflammasomes have been implicated. Inflammasomes are molecule complexes that are assembled in response to microbial components or cellular danger signals and facilitate the production of bioactive pro-inflammatory cytokines. One inflammasome in particular, NLRP3, has been analysed extensively in its contribution to colitis and has been shown to be associated with the development of colitis-associated colorectal cancer. This review will summarise the role of NLRP3 in intestinal inflammation, discuss some of the triggers of inflammation in the gastrointestinal tract such as diet and introduce some opportunities to use this inflammasome as therapeutic target for the treatment of colitis and colitis-associated colorectal cancer. |
